News Medical on MSN
Blocking a cancer-related pathway helps reduce spine deformities due to genetic disorder, finds new study
In a new study, researchers from France have revealed why people with neurofibromatosis type 1 (NF1) often develop serious ...
Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to reduce the number of fractures per year, sending its shares plunging 43.5% ...
Studies by University of Birmingham researchers suggest that a naturally occurring peptide known as PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration), could represent a promising potential ...
Ultragenyx Pharmaceutical said on Monday late-stage studies showed its experimental drug for a type of genetic bone disease failed to reduce the number of fractures that occurred per year. Shares of ...
Scientists uncovered how the protein Piezo1 translates physical activity into stronger bones, offering a path to ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...
Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...
Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone disease, setrusumab, failed a pair of phase 3 trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback